Similarly, in a study involving 73 NSCLC patients treated with EGFR‐TKIs, Matsuo et al.26reported that a longer duration of treatment was independently associated with T790M mutation in a multivariate logistic analysis (≤10 vs. >10 months, OR 0.09, p < 0.001). Here, EGFR is linked to non-small cell lung carcinoma.